ISACA
17.1.2023 18:38:35 CET | Business Wire | Press release
Privacy is a critical component of digital trust – it contributes to a more positive reputation and fewer cybersecurity incidents for the companies that prioritise it. Global digital trust association, ISACA, believes that businesses are aware of its significance; according to its 2023 “Privacy in Practice” report published today, 87% of organisations in Europe offer privacy awareness training to employees. But they’re missing the mark as most (94%) companies recognise a privacy skills gap within their business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005916/en/
ISACA surveyed more than 1,800 professionals worldwide—including 375 in Europe—who work in data privacy or have detailed knowledge of the data privacy function within their organisations to demonstrate current perspectives on privacy staffing, organisation structure, frameworks and policies, budgets, training, and data breaches. Learn more about the key findings and the business benefits of privacy by design at www.isaca.org/privacy-month-2023. (Graphic: ISACA)
ISACA’s “Privacy in Practice” report explores the state of enterprise privacy by examining trends around privacy teams, privacy-related challenges, privacy by design and the future of privacy.
The report reveals that as it stands, more than half (59%) of technical privacy teams in Europe are understaffed. Building these departments is a challenge, with 1 in 5 businesses saying it takes them more than six months to fill a technical privacy position and 41% saying their privacy budgets are underfunded.
The most reported privacy failures include a lack of training or poor training (49%); data breaches (38%); and not practicing privacy by design (39%). With just 38% of business leaders confident in their organisation’s ability to ensure the privacy of its sensitive data, businesses need to change their approach to closing the privacy skills gap or risk jeopardising their relationships with customers and damaging the reputation of the business.
Chris Dimitriadis, Global Chief Strategy Officer, ISACA says: “Privacy professionals play a key role in establishing digital trust. As technology advances, introducing new complexities and threats and as the cyberthreat landscape increases in size and sophistication, demand for these individuals is only going to grow. Heightened privacy skills demand is good news for candidates with privacy technology knowledge but also bad news for businesses that are struggling to close the privacy skills gap. As our new research highlights, businesses need to consider changing their training programmes and adopt privacy by design to limit the number of privacy breaches, build digital trust, and set the business up for long term success.”
Tony Hughes, ISACA Emerging Trends Working Group Member, adds: “Only searching for candidates with specific experience and technical privacy skills is an outdated mindset – it immediately limits businesses to a small pool of people. Instead, organisations need to lean on reskilling people in non-privacy roles, using contract employees and focusing on individuals with the right soft skills to reduce the privacy skills gap.”
Notes to Editors
All figures are based on fieldwork conducted by ISACA. Fieldwork was undertaken in Q4 2022, amongst 1890 global privacy professionals, including 375 in Europe.
ISACA’s Privacy in Practice report is now available to download here.
About ISACA
For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organisations, and build a more trusted and ethical digital world. ISACA leverages the expertise of its more than 165,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality, with a presence in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for under resourced and underrepresented populations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005916/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
